Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)

NeOnc to present NEO100 and NEO212 data at SNO meeting on November 13, 2026

Neutral Impact 2 of 5 product/contract Written later

NeOnc Technologies Holdings announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on November 13, 2026, at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. The filing is an announcement of scheduled presentations and contains no financial results, guidance, or new financing terms.

Key points

  • Two poster presentations scheduled for Friday, November 13, 2026, 7:30 to 9:30 p.m. EST, at the Pennsylvania Convention Center in Philadelphia
  • NEO100 poster: updated Phase 1/2a results in recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma, presented by Thomas C. Chen, MD, PhD
  • NEO212 poster: Phase 1 safety, pharmacokinetics and early activity signals in TMZ-Resistant recurrent GBM, presented by Josh Neman, PhD
  • Both NEO100 and NEO212 remain investigational and have not been approved by any regulatory authority

The filing

CompanyNEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Form8-K, current report
Filed with the SECNov 3, 2026, 5:00 PM ET
Accession number0001829126-26-011937

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.